Last Updated: 16/07/2024
Multi-Stage Malaria Vaccine Consortium (MMVC): A four-strike vaccine against malaria
Objectives
To test a novel vaccine combination targeting four stages of the malaria parasite life cycle.
European Vaccine Initiative (EVI), Germany
Ifakara Health Institute (IHI), Tanzania
Institute of Research for Development (IRD), Benin, Benin
Health Action Research Group (GRAS), Burkina Faso
London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom
Novavax, United States
Janssen Infectious Diseases and Vaccines, United States
Serum Institute of India, India
Institute of Sciences and Techniques (INSTech), Burkina Faso
Clinical Research Unit of Nanoro (CRUN), Burkina Faso
University of Sierra Leone (USL), Sierra Leone
Safety and immunogenicity of a protein particle malaria vaccine candidate, R21, administered with and without Matrix-M1 in healthy UK volunteers.
A Phase Ib multi-stage Plasmodium Falciparum malaria vaccine study to assess the experimental malaria vaccines RH5.2-VLP and R21.
A study to determine if a new Malaria vaccine is safe and induces immunity among Kenyan adults, young children and infants.
A Phase III Randomized Controlled Multi-Centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical Malaria.
A Phase I study to assess the safety and immunogenicity of a protein particle malaria vaccine candidate, R21, administered with AS01B in healthy UK volunteers
A Phase Ib trial to evaluate the safety and immunogenicity of R21/Matrix-M in a single and two vial presentation, with different immunisation schedules, and when co-administered with EPI vaccines in African children.
A Phase Ib/IIb Randomised Controlled Trial of the safety, immunogenicity and efficacy of a candidate malaria vaccine, R21 adjuvanted with Matrix-M (R21/MM), in 5-17 month old children in Nanoro, Burkina Faso
A Phase I/IIa Sporozoite challenge study to assess the safety and protective efficacy of adjuvanted R21 at two different doses and the combination malaria vaccine candidate regimen of adjuvanted R21 + ChAd63 and MVA Encoding ME-TRAP.
A Phase Ib trial to evaluate the safety and immunogenicity of R21/Matrix-M™ in African children living with HIV.
A Phase Ib Randomised, Controlled, Single-blind study to assess the safety, immunogenicity of the malaria vaccine candidate R21 With Matrix-M1 adjuvant in West African adult volunteers
Safety, immunogenicity, and efficacy of R21/Matrix-M and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults.
A Phase I/IIa sporozoite challenge study to assess the safety, immunogenicity and protective efficacy of adjuvanted R21, administered in different dose Schedules in healthy UK volunteers
Phase Ib age de-escalation and dose escalation of Pfs25-IMX313/Matrix-M intramuscularly in healthy adults and young children in Tanzania
Safety and immunogenicity of Rh5.1/Matrix-M in healthy adults and infants in Tanzania
Age de-escalation study of BK-SE36/CpG intramuscularly in healthy malaria exposed African adults and children living in Burkina Faso
The malaria parasite has a complex life cycle, spanning mosquitoes and humans. When injected into the bloodstream following the bite of an infected mosquito, it first invades and multiplies within liver cells, before seeking refuge and multiplying again in red blood cells. When these burst, parasites circulating in the bloodstream can be taken up by a feeding mosquito.
Although only a single cell, the parasite is a master of disguise, adopting entirely different forms at different stages of its life cycle. Malaria vaccine developers typically focus on one specific stage of the life cycle. The only licensed malaria vaccine, RTS,S, targets the initial human stage, to prevent liver infection. However, a vaccine targeting the final bloodstream stage could block transmission to mosquitoes.
The four-stage vaccine will include a next-generation version of RTS,S, known as R21; a liver-stage vaccine that has shown positive results in EDCTP-funded trials; a promising vaccine targeting a key protein involved in red blood cell invasion, PfRH5; and a vaccine targeting a key protein in the final bloodstream form, Pfs25.
Results from a series of controlled human infection studies – using new capacity in Africa – and pilot trials will inform the design of an appropriate vaccination strategy. This will be tested in a phase II trial in infants in sites of different levels of malaria transmission. The project will also build capacity to test the vaccine in adults as a possible way of blocking transmission to mosquitoes in malaria elimination campaigns.
European vaccine initiative MMVC detailsEDCTP Portfolio Malaria details
Apr 2018 — Sep 2023
$18.48M
Related Resources
No related items found
Related Projects
No related items found
